by Admin | Jul 28, 2026 | Quarterly Newsletter
During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, FibroFighters Foundation presented important research on Fibrolamellar Carcinoma (FLC). Using our customized FLC Tumor Portrait, we have now built a dataset of over 120 Fibrolamellar... by Admin | Jul 28, 2026 | Uncategorized
Natera now offers two versions of their Signatera ctDNA blood test, and both work the same basic way: they analyze a patient’s tumor tissue once to build a personalized “fingerprint” of that cancer, then use blood draws over time to check whether... by Admin | Jul 28, 2026 | Uncategorized
We are deeply grateful to Dr. Nagourney and his entire team at the Nagourney Cancer Institute for presenting the results of his latest study during the ASCO Annual Meeting this year. This exciting study offers hope for new and novel treatment options. See what was... by Admin | Jul 28, 2026 | Quarterly Newsletter
For half a decade, FibroFighters Foundation and xCures have worked side by side to build something rare cancer research desperately needs: a living, growing patient registry that turns real FLC experiences into real research data. We will be reintroducing the FLC... 